Skip to Content
Merck
  • Microglia replacement by microglia transplantation (Mr MT) in the adult mouse brain.

Microglia replacement by microglia transplantation (Mr MT) in the adult mouse brain.

STAR protocols (2021-07-27)
Zhen Xu, Bo Peng, Yanxia Rao
ABSTRACT

Mutations in microglia may cause brain disorders. Replacement of dysfunctional microglia by allogeneic wild-type microglia from bone marrow transplantation (Mr BMT) or peripheral blood can correct the gene deficiency at the brain-wide scale but cannot achieve precise replacement at specific brain regions. Here, we introduce a strategy with potential clinical relevance-microglia replacement by microglia transplantation (Mr MT), combining tamoxifen-induced ablation of Mr BMT cells and intracranial injection of microglia to mouse brain, to achieve region-sepcific microglia replacement. The original abbreviation of this microglia replacement strategy is mrMT. We hereby change the name to Mr MT. For complete details on the use and execution of this protocol, please refer to Xu et al. (2020).

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Xylazine hydrochloride, ≥99.0% (HPLC)
Sigma-Aldrich
Cholesterol, Sigma Grade, ≥99%
Sigma-Aldrich
apo-Transferrin human, powder, BioReagent, suitable for cell culture, ≥98% (agarose gel electrophoresis)
Sigma-Aldrich
L-Cysteine, 97%
Sigma-Aldrich
N-Acetyl-L-cysteine, BioReagent, suitable for cell culture
Sigma-Aldrich
Oleic acid, BioReagent, suitable for cell culture
Sigma-Aldrich
Meloxicam sodium salt hydrate, ≥98% (HPLC)
Sigma-Aldrich
Dimethyl sulfoxide, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
cis-11-Eicosenoic acid, ≥99% (capillary GC)